NOV/CCN3 Antibody (130) [DyLight 680]
Novus Biologicals, part of Bio-Techne | Catalog # NBP2-89369FR
Recombinant Monoclonal Antibody
Conjugate
Catalog #
Key Product Details
Species Reactivity
Validated:
Human
Applications
ELISA
Label
DyLight 680 (Excitation = 692 nm, Emission = 712 nm)
Antibody Source
Recombinant Monoclonal Rabbit IgG Clone # 130
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Product Summary for NOV/CCN3 Antibody (130) [DyLight 680]
Immunogen
This antibody was obtained from a rabbit immunized with purified, recombinant Human NOV/CCN3 (Accession#: NP_002505.1; Met 1-Met 357).
Specificity
No cross-reactivity in ELISA with:
Human WISP1
Clonality
Monoclonal
Host
Rabbit
Isotype
IgG
Applications for NOV/CCN3 Antibody (130) [DyLight 680]
Application
Recommended Usage
ELISA
Optimal dilutions of this antibody should be experimentally determined.
Application Notes
Optimal dilution of this antibody should be experimentally determined.
Please Note: Optimal dilutions of this antibody should be experimentally determined.
Formulation, Preparation, and Storage
Purification
Protein A purified
Formulation
50mM Sodium Borate
Preservative
0.05% Sodium Azide
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C in the dark.
Background: NOV/CCN3
Long Name
Nephroblastoma Overexpressed Gene
Alternate Names
CCN3, IGFBP-9
Gene Symbol
CCN3
Additional NOV/CCN3 Products
Product Documents for NOV/CCN3 Antibody (130) [DyLight 680]
Product Specific Notices for NOV/CCN3 Antibody (130) [DyLight 680]
DyLight (R) is a trademark of Thermo Fisher Scientific Inc. and its subsidiaries.
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...